Advertisement

Clinical Research in Cardiology

, Volume 109, Issue 1, pp 96–102 | Cite as

Atrial high-rate episodes and risk of major adverse cardiovascular events in patients with cardiac implantable electronic devices

  • Daniele Pastori
  • Kazuo Miyazawa
  • Yanguang Li
  • Orsolya Székely
  • Farhan Shahid
  • Alessio Farcomeni
  • Gregory Y. H. LipEmail author
Original Paper

Abstract

Background

Patients with atrial high-rate episodes (AHREs) are at higher risk of thromboembolic events and mortality. The risk of major adverse cardiovascular events (MACE) in these patients is unknown.

Objective

To investigate the risk of MACE in patients implanted with cardiac implantable electronic devices (CIEDs) developing AHREs

Methods and results

We included 852 consecutive patients undergoing CIEDs implantation. Primary outcome was a composite endpoint of MACEs occurring after AHREs ≥ 5 min. AHRE was defined as > 175 bpm and lasting ≥ 5 min. We also performed a subgroup analysis in patients with the longest AHRE lasting ≥ 24 h. Cox regression analysis with time-dependent covariates was used to investigate the relationship between AHREs and MACEs.

Mean age was 70.0 ± 13.6 years, and 39.3% were women: 325 patients developed AHREs ≥ 5 min [incidence rate (IR) 13.1% year 95% confidence interval (CI) 11.7–14.6] and 124 patients developed AHREs ≥ 24 h (IR 3.7%/year 95% CI 3.1–4.5). During a median follow-up of 37.0 months (IQR 19.0–64.3, 316,132 patient-years), 152 MACEs occurred (IR 4.85%/year, 95% CI 4.11–5.68). The IR of MACE occurring after AHREs onset was higher in patients developing AHREs ≥ 24 h (IR 1.13%/year) than AHREs ≥ 5 min (IR 0.63%/year, p = 0.030).

Multivariable Cox regression analysis showed that AHREs ≥ 5 min (HR 1.788, 95% CI 1.247–2.562, p = 0.002), diabetes (HR 1.909, 95% CI 1.358–2.683, p < 0.001), heart failure (HR 2.203, 95% CI 1.527–3.178, p < 0.001), and coronary artery disease (HR 1.862, 95% CI 1.293–2.681, p = 0.001) were associated to MACE. This association was even stronger for AHREs ≥ 24 h (HR 2.390, 95% CI 1.481–3.857, p < 0.001).

Conclusions

Patients implanted with CIEDs developing AHREs show a significant risk for MACE, which is dependent on AHREs burden. Cardiovascular prevention strategies in this patient population are warranted.

Graphic abstract

Keywords

AHREs CIED MACE Implantable device Pacemaker Atrial fibrillation Myocardial infarction Cardiovascular risk 

Notes

Funding

None directly related to this manuscript.

Compliance with ethical standards

Conflict of interest

None related to this paper.

References

  1. 1.
    Gorenek BC, Bax J, Boriani G, Chen SA, Dagres N, Glotzer TV, Healey JS, Israel CW, Kudaiberdieva G, Levin LA, Lip GYH, Martin D, Okumura K, Svendsen JH, Tse HF, Botto GLC-C, Group ESCSD (2017) Device-detected subclinical atrial tachyarrhythmias: definition, implications and management—an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 19(9):1556–1578.  https://doi.org/10.1093/europace/eux163 CrossRefGoogle Scholar
  2. 2.
    Di Cori A, Lilli A, Zucchelli G, Zaca V (2018) Role of cardiac electronic implantable device in the stratification and management of embolic risk of silent atrial fibrillation: are all atrial fibrillations created equal? Expert Rev Cardiovasc Ther 16(3):175–181.  https://doi.org/10.1080/14779072.2018.1438267 CrossRefPubMedGoogle Scholar
  3. 3.
    Miyazawa K, Pastori D, Lip GYH (2018) Quantifying time in atrial fibrillation and the need for anticoagulation. Prog Cardiovasc Dis 60(4–5):537–541.  https://doi.org/10.1016/j.pcad.2017.12.002 CrossRefPubMedGoogle Scholar
  4. 4.
    Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, Investigators A (2012) Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 366(2):120–129.  https://doi.org/10.1056/NEJMoa1105575 CrossRefPubMedGoogle Scholar
  5. 5.
    Freedman B, Boriani G, Glotzer TV, Healey JS, Kirchhof P, Potpara TS (2017) Management of atrial high-rate episodes detected by cardiac implanted electronic devices. Nat Rev Cardiol 14(12):701–714.  https://doi.org/10.1038/nrcardio.2017.94 CrossRefPubMedGoogle Scholar
  6. 6.
    Camm AJ, Simantirakis E, Goette A, Lip GY, Vardas P, Calvert M, Chlouverakis G, Diener HC, Kirchhof P (2017) Atrial high-rate episodes and stroke prevention. Europace Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 19(2):169–179.  https://doi.org/10.1093/europace/euw279 CrossRefGoogle Scholar
  7. 7.
    Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, Camm JA, Singer DE (2014) Device-detected atrial fibrillation and risk for stroke: an analysis of %3e10,000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices). Eur Heart J 35(8):508–516.  https://doi.org/10.1093/eurheartj/eht491 CrossRefPubMedGoogle Scholar
  8. 8.
    Miyazawa K, Pastori D, Li YG, Szekely O, Shahid F, Boriani G, Lip GYH (2019) Atrial high rate episodes in patients with cardiac implantable electronic devices: implications for clinical outcomes. Clin Res Cardiol.  https://doi.org/10.1007/s00392-019-01432-y CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG, Halperin JL, Investigators I (2015) Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices. Eur Heart J 36(26):1660–1668.  https://doi.org/10.1093/eurheartj/ehv115 CrossRefPubMedGoogle Scholar
  10. 10.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Authors/Task Force M, Document R (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS: the Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC endorsed by the European Stroke Organisation (ESO). Eur Heart J.  https://doi.org/10.1093/eurheartj/ehw210 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd S, Howard VJ, Howard G, Herrington DM, Cushman M (2014) Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 174(1):107–114.  https://doi.org/10.1001/jamainternmed.2013.11912 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Pastori D, Pignatelli P, Angelico F, Farcomeni A, Del Ben M, Vicario T, Bucci T, Raparelli V, Cangemi R, Tanzilli G, Lip GY, Violi F (2015) Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest 147(6):1644–1650.  https://doi.org/10.1378/chest.14-2414 CrossRefPubMedGoogle Scholar
  13. 13.
    Pastori D, Miyazawa K, Li Y, Shahid F, Hado H, Lip GYH (2018) Inflammation and the risk of atrial high-rate episodes (AHREs) in patients with cardiac implantable electronic devices. Clinical Res Cardiol 107(9):772–777.  https://doi.org/10.1007/s00392-018-1244-0 CrossRefGoogle Scholar
  14. 14.
    Jacobsson J, Platonov PG, Reitan C, Carlsson J, Borgquist R (2017) Atrial high-rate episodes predict clinical outcome in patients with cardiac resynchronization therapy. Scand Cardiovasc J 51(2):74–81.  https://doi.org/10.1080/14017431.2016.1260768 CrossRefPubMedGoogle Scholar
  15. 15.
    Shibata T, Kawakami S, Noguchi T, Tanaka T, Asaumi Y, Kanaya T, Nagai T, Nakao K, Fujino M, Nagatsuka K, Ishibashi-Ueda H, Nishimura K, Miyamoto Y, Kusano K, Anzai T, Goto Y, Ogawa H, Yasuda S (2015) Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism. Circulation 132(4):241–250.  https://doi.org/10.1161/CIRCULATIONAHA.114.015134 CrossRefPubMedGoogle Scholar
  16. 16.
    Violi F, Soliman EZ, Pignatelli P, Pastori D (2016) Atrial fibrillation and myocardial infarction: a systematic review and appraisal of pathophysiologic mechanisms. J Am Heart Assoc.  https://doi.org/10.1161/JAHA.116.003347 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Kirchhof P, Blank BF, Calvert M, Camm AJ, Chlouverakis G, Diener HC, Goette A, Huening A, Lip GYH, Simantirakis E, Vardas P (2017) Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the non-vitamin K antagonist oral anticoagulants in patients with atrial high rate episodes (NOAH-AFNET 6) trial. Am Heart J 190:12–18.  https://doi.org/10.1016/j.ahj.2017.04.015 CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lee CJ, Gerds TA, Carlson N, Bonde AN, Gislason GH, Lamberts M, Olesen JB, Pallisgaard JL, Hansen ML, Torp-Pedersen C (2018) Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 72(1):17–26.  https://doi.org/10.1016/j.jacc.2018.04.036 CrossRefPubMedGoogle Scholar
  19. 19.
    Schupp T, Akin I, Reiser L, Bollow A, Taton G, Reichelt T, Ellguth D, Engelke N, Ansari U, Mashayekhi K, Weiss C, Nienaber C, Akin M, Borggrefe M, Behnes M (2019) Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population. Clin Res Cardiol.  https://doi.org/10.1007/s00392-019-01416-y CrossRefPubMedGoogle Scholar
  20. 20.
    De Vincentis G, Frantellizzi V, Fedele F, Farcomeni A, Scarparo P, Salvi N, Fegatelli DA, Mancone M, Verschure DO, Verberne HJ (2018) Role of cardiac (123)I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD. J Nucl Cardiol.  https://doi.org/10.1007/s12350-018-1258-z CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Martens P, Nuyens D, Rivero-Ayerza M, Van Herendael H, Vercammen J, Ceyssens W, Luwel E, Dupont M, Mullens W (2019) Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol.  https://doi.org/10.1007/s00392-019-01440-y CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Institute of Applied Health ResearchUniversity of BirminghamBirminghamUK
  2. 2.Department of Internal Medicine and Medical Specialties, I Clinica Medica, Atherothrombosis CenterSapienza University of RomeRomeItaly
  3. 3.Department of Cardiology, Chinese PLA Medical SchoolChinese PLA General HospitalBeijingChina
  4. 4.Department of Public Health and Infectious DiseasesSapienza University of RomeRomeItaly
  5. 5.Liverpool Centre for Cardiovascular ScienceUniversity of Liverpool and Liverpool Heart and Chest HospitalLiverpoolUK
  6. 6.Aalborg Thrombosis Research Unit, Department of Clinical MedicineAalborg UniversityAalborgDenmark

Personalised recommendations